|
Match
|
Document |
Document Title |
|
|
6670139 |
Cell-free assay using oncogene-induced apoptosis to identify inhibitors of apoptosis in drug-resistant cells
The present invention relates to a method of identifying a compound (agent) which modulates apoptosis in transformed cells. In one embodiment, the invention is a method of identifying a compound...
|
|
|
6670146 |
Regulatory T cells; methods
Methods for increasing yields of regulatory T cells, useful, e.g., in transplantation contexts. Use of antigen presenting cells and anti-CD28 are also described.
|
|
|
6667175 |
Generation of antigen specific T suppressor cells for treatment of rejection
This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor...
|
|
|
6663859 |
Compositions for enhancing the immune response
D-Ribose and methods for using D-Ribose are provided for enhancing the immune response in mammals. Those with a less than optimal immune response will benefit from oral or parenteral administration...
|
|
|
6660467 |
Variant of ciliary neurotrophic factor and DNA encoding the variant
The subject of the present invention are variants of ciliary neurotrophic factor with enhanced receptor selectivity (CNTFR), useful for the treatment of diseases and disorders including motor...
|
|
|
6656688 |
Antisense modulation of NF-kappa-B p65 subunit expression
Antisense compounds, compositions and methods are provided for modulating the expression of NF-kappa-B p65 subunit. The compositions comprise antisense compounds, particularly antisense...
|
|
|
6656731 |
Nucleic acid catalysts with endonuclease activity
The present invention relates to nucleic acid molecules with new motifs having catalytic activity, methods of syntheses and uses thereof.
|
|
|
6656917 |
Compositions and methods for targeted enzymatic release of cell regulatory compounds
Novel pro-drugs and methods for their use to alter the growth and biological characteristics of living cells, tissues, or whole organisms are described. The methods allow for selective activation...
|
|
|
6656732 |
Antisense inhibition of src-c expression
Antisense compounds, compositions and methods are provided for modulating the expression of src-c. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted...
|
|
|
6656730 |
Oligonucleotides conjugated to protein-binding drugs
Ligand-conjugated oligomeric compounds are described wherein ligands are conjugated to one or more sites on an oligomeric compound including the 2′-, 3′-, 5′-, nucleobase and internucleotide...
|
|
|
6653135 |
Dynamic protein signature assay
An assay to determine the specific expression and suppression of proteins in response to a stressor is disclosed. An organism exposed to a stressor, including disease caused by exposure to, e.g., a...
|
|
|
6653132 |
IRES sequences with high translational efficiency and expression vectors containing the sequence
An isolated and cloned translation control element, and analogues thereof, having the nucleotide sequence as set forth in SEQ ID NO:7 and designated SP163, are disclosed. The translation control...
|
|
|
6653133 |
Antisense modulation of Fas mediated signaling
Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods...
|
|
|
6649596 |
Modified VEGF Oligonucleotides for Inhibition of tumor growth
Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides...
|
|
|
6649595 |
Regulation of biological events using novel compounds
Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
|
|
|
6649411 |
Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for...
|
|
|
6645764 |
Neocartilage and methods of use
Disclosed are neocartilage compositions characterized by having multiple layers of cells, said cells being surrounded by a substantially continuous insoluble glycosaminoglycan and collagen-enriched...
|
|
|
6642353 |
Peptide ligands for the erythropoietin receptor
Clones isolated from phage display libraries that bound to an erythropoietin (EPO) receptor probe are disclosed. Peptides encoded by sequences of those clones that bound to the EPO receptor are...
|
|
|
6638765 |
Platform for the differentiation of cells
The present invention relates to an in vitro method for islet cell expansion, which comprises the steps of: a) preparing dedifferentiated cells derived from cells in or associated with post-natal...
|
|
|
6635802 |
Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors
Provided are methods and compositions for increasing the efficiency of nuclear transfer using apoptosis inhibitors, and for the production of transgenic and non-transgenic mammals from cultured...
|
|
|
6632667 |
Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
The present invention provides methods of modulating the shedding of L-selectin in cells or tissues using an inhibitor of TACE expression or activity. Antisense oligonucleotides targeted to nucleic...
|
|
|
6632630 |
Monooxygenase assays
Cytochrome P-450 assay methods and kits for the methods are provided employing a cytochrome P-450 enzyme, substrates characterized by having an oxidizable methylene group oxidized to an aldehyde...
|
|
|
6632668 |
Monolayer sheet structure of primary hepatocytes obtained using a protein-phosphorylation inhibitor
A monolayer sheet structure is prepared containing a confluent monolayer of primary hepatocytes cultured on a substrate in sheet form. The monolayer sheet structure is formed by treating the...
|
|
|
6630324 |
Aldehyde reductase bidirectional promoter and its use
The invention relates to an aldehyde reductase bidirectional promoter which promotes transcription of two different sequences linked in opposite orientations. Vectors containing said promoter and...
|
|
|
6627191 |
Anti-transforming growth factor Beta (TGF-β) treated stem cell composition and method
The invention relates to stem cell compositions comprising anti-TGF-β treated stem cells which are viable for at least 14 days in culture without replication or differentiation and methods for...
|
|
|
6627615 |
Methods and compositions for in vivo gene therapy
Novel methods and compositions are provided for introducing a gene capable of modulating the genotype and phenotype into two or more tissues following systemic administration. The gene can be...
|
|
|
6623962 |
Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
Enzymatic nucleic acid molecules which cleave EGFR RNA.
|
|
|
6620585 |
Use of ectoenzymes and secreted enzymes to monitor cellular proliferation
The present invention relates to methods of measuring cellular proliferation using ectoenzymes such as membrane-bound chitobiase (N,N′-diacetylchitobiase) and nucleic acids for use in such methods.
|
|
|
6617158 |
Method for stimulating the production of fetal hemoglobin producing erythroid cells
The present invention provides a method for ameliorating β-globin disorders in a mammal. In one aspect of the invention, the treatment involves ex vivo treatment of early erythroid progenitor...
|
|
|
6617162 |
Antisense modulation of estrogen receptor alpha expression
Antisense compounds, compositions and methods are provided for modulating the expression of estrogen receptor alpha. The compositions comprise antisense compounds, particularly antisense...
|
|
|
6617161 |
Serum-free cell growth medium
A chemically defined-serum free growth medium for the in vitro and ex vivo of cells and cell lines. The medium consists of about a one to one ratio (v/v) of two basal growth media containing...
|
|
|
6613567 |
Antisense inhibition of Her-2 expression
Antisense compounds, compositions and methods are provided for modulating the expression of Her-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted...
|
|
|
6613506 |
Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
The present invention relates to nucleic acid molecules involved in HIV infection, proteins encoded by such nucleic acid molecules, and protective compounds including such nucleic acid molecules,...
|
|
|
6613568 |
Hematopoietic differentiation of human embryonic stem cells
Disclosed herein are methods of obtaining human hematopoietic cells from human embryonic stem cells using mammalian stromal cells. Hematopoietic cells derived in this way are useful for creating...
|
|
|
6610540 |
Low oxygen culturing of central nervous system progenitor cells
The present invention relates to the growth of cells in culture under conditions that promote cell survival, proliferation, and/or cellular differentiation. The present inventors have found that...
|
|
|
6610541 |
Recombinant, active caspases and uses thereof
Rev-caspases comprising a primary product in which the small subunit is N-terminal to the large subunit are provided. Rev-caspases are used for screening and identifying caspase inhibitors and...
|
|
|
6610539 |
Antisense oligonucleotide sequences as inhibitors of microorganisms
This invention relates to antisense oligonucleotides which modulate the expression of the ribonucleotide reductase or the secA genes in microorganisms. This invention is also related to methods of...
|
|
|
6607915 |
Antisense inhibition of E2A-Pbx1 expression
Compounds, compositions and methods are provided for inhibiting E2A-Pbx1 mediated transformation. The compositions comprise antisense compounds targeted to nucleic acids encoding E2A-Pbx1. Methods...
|
|
|
6607916 |
Antisense inhibition of Casein kinase 2-alpha expression
Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-alpha. The compositions comprise antisense compounds, particularly antisense...
|
|
|
6605467 |
Fusion protein comprising the whole or part of the PP65 protein of human CMV, useable in particular for preparing a vaccine
The invention concerns a fusion protein characterised in that it comprises at least part of the pp65 protein of the cytomegalovirus (or CMV), or a protein having at least 80% homology with the pp65...
|
|
|
6602858 |
Nucleic acid catalysts comprising L-nucleotide analogs
A nucleic acid catalyst comprising at least one L-nucleotide substitution.
|
|
|
6602710 |
Screening method for SREBP pathway-specific inhibitors
This invention provides a screening method for sterol regulatory element binding protein (SREBP) pathway-specific inhibitors using a mutant cultured cell, as well as therapeutic agents for...
|
|
|
6599742 |
Antisense oligonucleotide inhibition of human serine/threonine protein phosphatase gene expression
Oligonucleotides are provided which are targeted to nucleic acids encoding human serine/threonine protein phosphatases and which are capable of inhibiting protein phosphatase expression. Methods of...
|
|
|
6596473 |
Active survival domains of IGF-IR and methods of use
Active Survival Domains in the Insulin-like Growth Factor-I Receptor (IGF-IR) required for transmitting the survival signal in vertebrate cells have been identified. In FL5.12 cells transfected...
|
|
|
6596537 |
Human interleukin-6 receptor expression inhibitor
The present invention discloses an expression inhibitor of human interleukin-6 receptor (human IL-6R) comprising as its active ingredient an antisense oligonucleotide derivative that hybridizes to...
|
|
|
6593511 |
Models of chronic and acute inflammatory diseases
Methods and compositions are provided for the creation and screening of non-human animal models having chronic inflammation. Immunocompromised host animals are injected with a population of...
|
|
|
6593139 |
Initiation of full mammalian oocyte activation by multiple sperm components
The invention provides a microinsertion-based, trans-complementation method of in vitro oocyte activation useful to identify properties of sperm-borne oocyte-activating factor(s) (SOAF) and...
|
|
|
6589728 |
Methods for isolation and activation of, and control of differentiation from, stem and progenitor cells
The present invention provides a method of isolating, maintaining, and/or enriching for stem or progenitor cells derived from diverse organ or tissue sources. The invention specifically teaches...
|
|
|
6589747 |
Method for identifying compounds that modulate the interaction of amyloid beta or its aggregates with a voltage gated sodium channel
Among other things, assays and methods of diagnosis and treatment of disease (e.g., Alzheimer's disease) based on the surprising observation of an interaction between amyloid β or its aggregates...
|
|
|
6589505 |
Cells that lack p19ink4d and p27kip1 activity and methods of use thereof
Non-human animals that have been manipulated so as not to express a functional p19 INK4d and p27 KIP1 proteins are described. One particular non-human animal exemplified is a p19 INK4d -double...
|